November 2021 Twist Bioscience Launches Revelar Biotherapeutics to Develop and Commercialize Novel COVID offering of high-quality synthetic DNA using its silicon platform, today announced it has launched Revelar Biotherapeutics, Inc., an independently operated, new biotechnology company to develop and commercialize In addition, Revelar will have the ability to leverage the antibody discovery and optimization platform

October 2022 "Over three decades of research have provided thorough insights into G protein-coupled receptor (GPCR) regulation. In a recent issue of Molecular Cell, Fonseca et al. identified a previously overlooked desensitization mechanism. Agonist activation of the β2-adrenoceptor (β2AR) causes its S-nitrosylation that is required for the receptor to internalize and desensitize. Eliminating β2AR S-nitrosylation by mutation of C265 augments β2AR protein kinase A signaling, enables β2AR nitric oxide (NO) signaling, renders mice resistant to bronchoconstriction, and protects mice from allergen-induced asthma." Read more at the source #DrGPCR #GPCR #IndustryNews

September 2022 "The follicle-stimulating hormone receptor (FSHR) belongs to the glycoprotein hormone receptors, a subfamily of G-protein-coupled receptors (GPCRs). FSHR is involved in reproductive processes such as gonadal development and maturation. Structurally, the extensive extracellular domain, which contains the hormone-binding site and is linked to the transmembrane domain by the hinge region (HR), is characteristic for these receptors. How this HR is involved in hormone binding and signal transduction is still an open question. We combined in vitro and in situ chemical crosslinking, disulfide pattern analysis, and mutation data with molecular modeling to generate experimentally driven full-length models. These models provide insights into the interface, important side-chain interactions, and activation mechanism. The interface indicates a strong involvement of the connecting loop. A major rearrangement of the HR seems implausible due to the tight arrangement and fixation by disulfide bonds. The models are expected to allow for testable hypotheses about signal transduction and drug development for GPHRs." Read more at the source #DrGPCR #GPCR #IndustryNews

TAS1R2/TAS2R3 receptor Frizzled BRET sensors based on bioorthogonal labeling of unnatural amino acids reveal Constitutive signal bias mediated by the human GHRHR splice variant 1 A Genetically Encoded F-19 NMR Probe Reveals cAMP generation determines biological responses to PTH type 1 receptor activation Systems approach reveals Trevena Adds Seasoned Biopharma Commercial Executive to Senior Leadership Team Twist Bioscience Launches Revelar Biotherapeutics to Develop and Commercialize Novel COVID-19 and Other Antibody Therapeutics for Difficult

< GPCR News < GPCRs in Oncology and Immunology Dynamic Phosphoproteomics of BRS3 Activation Reveals the Data analysis revealed that 27 phosphopeptides corresponding to six proteins were involved in the Hippo

upregulation of R-spondin 3 and intestinal epithelial proliferation. β 2 -Adrenoceptor agonist profiling reveals The full activation mechanism of the adenosine A 1 receptor revealed by GaMD and Su-GaMD simulations. Integrative model of the FSH receptor reveals the structural role of the flexible hinge region. SAR exploration of the non-imidazole histamine H 3 receptor ligand ZEL-H16 reveals potent inverse agonism Jan Steyaert Receives Prestigious Gabbay Award For Contributions To Structural Biology Preclinical biotherapeutics